The Psychedelic News Feed - Psychedelic Alpha
Your one-stop source for the latest coverage of psychedelics in the media: from policy and culture through to research and business.| Psychedelic Alpha
Your one-stop source for the latest coverage of psychedelics in the media: from policy and culture through to research and business.| Psychedelic Alpha
Q3 2025 saw just over $120M flow into psychedelics companies, with atai Life Sciences, Reunion Neuroscience, and Sensorium Therapeutics leading the way. Explore key trends, public vs. private dynamics, and how the markets are reacting to trial and regulatory news in our Q3 roundup.| Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical…| Psychedelic Alpha
Oregon Psilocybin Services (OPS) has now published its second dataset for 2025, with updates summarised in our Oregon Psilocybin Services Tracker. Here, we share a summary of the main takeaways for…| Psychedelic Alpha
Welcome to the inaugural issue of The Psychedelic Practitioner, a new publication for the evolving practice of psychedelic care.| Psychedelic Alpha
Topline results from the latest in our series of psychedelics investor surveys. For detailed analysis, subscribe to Pα+ today.| Psychedelic Alpha
MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…| Psychedelic Alpha
This morning, the UK’s Royal College of Psychiatrists published a Position Statement on psychedelics and related substances for medical use. Here, we briefly unpack the statement, as well as related…| Psychedelic Alpha
We present the psychedelic drug development pipeline in two ‘bullseye chart’ formats, as of Q3’2025.| Psychedelic Alpha
As the release of a CRL declining Lykos' therapy generates a strong reaction from MAPS, delve into what this new transparency could change.| Labiotech.eu
From a long stint at the European Medicines Agency’s (EMA) Office of Therapies for Neurological and Psychiatric Disorders to her present-day practice as a clinical psychiatrist at leading cancer…| Psychedelic Alpha
Explore our interactive database of psychedelic patent activity in August 2025 via our Pα+ interface.| Psychedelic Alpha
Last Thursday, FDA published the complete response letter (CRL) it sent to Lykos Therapeutics last year, when it rejected its MDMA for PTSD new drug application. Here, we take a closer look at the…| Psychedelic Alpha
FDA has published its complete response letter (CRL) to Lykos Therapeutics, citing durability, safety, and bias concerns in rejecting MDMA therapy for PTSD. Here, we very briefly unpack the letter.| Psychedelic Alpha
The FDA is pushing researchers to reduce their use of animal models and instead adopt ‘new approach methodologies’, like organoids and AI modelling. Here, Dr. Alaina Jaster speaks with psychedelic…| Psychedelic Alpha
One year after FDA’s rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD application, insiders and observers reflect on what went wrong and what comes next. This in-depth…| Psychedelic Alpha
Dr. Alaina Jaster speaks with Dr. Mark Geyer in a discussion that traces his path to psychedelics research, the field’s scientific and cultural shifts, and the role of the Heffter Research Institute.| Psychedelic Alpha
In part 2 of our series on campaign finance, new complaints filed by former staffers of the Massachusetts Yes on 4 psychedelics initiative to the Massachusetts Office of Campaign and Political Finance appear to contradict assertions from a senior campaign advisor that payments were done in accordance with state law.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany’…| Psychedelic Alpha
Materialist assumptions often ignore or dismiss the role of consciousness in shaping brain activity itself, argues Johns Hopkins' Dr. Christophe Morin. Neuroplasticity forces us to reconsider this oversight. The brain does not merely react; it is re-organized in response to intention, attention, and behavior. Studies in mindfulness and trauma recovery demonstrate that new neural pathways can form when individuals shift their patterns of thought and belief. These changes are not trivial: they ...| Essentia Foundation
Here, we share Dr. Alaina Jaster’s observations from the inaugural Neurobiology of Psychedelics Gordon Research Conference, where leading scientists gathered to explore various realms of psychedelic…| Psychedelic Alpha
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. ∎ Pα+ is read by the world’s leading drug…| Psychedelic Alpha
